Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Ginkgo Bioworks and Texas A&M University have been jointly awarded a research grant from the USDA APHIS via the NIFA AFRI to study SARS-CoV-2 in white-tailed deer populations in Texas. This news has led to an increase in Ginkgo Bioworks' share prices.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 4:05 pm

Ginkgo Bioworks and Texas A&M University have jointly received a research grant from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service. The grant is to study SARS-CoV-2 in white-tailed deer populations in Texas.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 11:07 am

Several US stocks recorded gains in Wednesday's trading session. MillerKnoll surged 27% after announcing better-than-expected Q1 results and FY24 EPS guidance above estimates. Biohaven, Ramaco Resources, SoundHound AI, Warrior Met Coal, Immunovant, PROS Holdings, Ginkgo Bioworks, Hayward Holdings, Sea Limited, TAL Education Group, Opendoor Technologies, WW International, IonQ, Stevanato Group, Peabody Energy Corporation, and Mattel also saw significant increases.

Portfolio Pulse from Lisa Levin

September 27, 2023 | 2:28 pm

Ginkgo Bioworks Holdings (DNA) announced a collaboration with Pfizer (PFE) for the discovery of RNA-based drug candidates. Pfizer will use Ginkgo's RNA technology for novel RNA molecule discovery and development. Ginkgo will receive an upfront payment and could receive up to $331 million in fees and milestone payments across three planned programs, along with potential royalties on future sales.

Portfolio Pulse from Adam Eckert

September 27, 2023 | 1:45 pm

Ginkgo Bioworks announced a multi-target RNA discovery collaboration with Pfizer. ShiftPixy announced its reverse stock 1-for-24 split effective date, causing its shares to trade higher. Cardiff Oncology announced positive clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity from Onvansertib monotherapy.

Portfolio Pulse from ryanfaloona@benzinga.com

September 27, 2023 | 12:40 pm

Ginkgo Bioworks has announced a collaboration with Pfizer to discover RNA-based drug candidates, leading to a rise in Ginkgo's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:25 pm

Ginkgo Bioworks has entered into a collaboration with Pfizer for the discovery of RNA-based drug candidates. Ginkgo will receive an upfront payment and could potentially receive up to $331 million in research fees and development and commercial milestone payments across three programs.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:04 am

Ginkgo Bioworks has signed a memorandum of understanding to develop and implement new biosecurity capabilities in Madagascar. The company's biosecurity unit, Concentric by Ginkgo, will provide infrastructure and tools to support Madagascar's public health institutions in their fight against COVID-19 and other biological threats.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 11:11 am

Ark Invest, led by Cathie Wood, sold Tesla shares worth $15.94 million and bought Palantir shares worth $14.92 million. The transactions were executed through ARK Innovation ETF, ARK Next Generation Internet ETF, and Ark’s Fintech Innovation ETF. Ark Invest also sold DraftKings shares and bought Ginkgo Bioworks and Teladoc shares.

Portfolio Pulse from Benzinga Neuro

September 22, 2023 | 3:20 am

Ark Invest, led by Cathie Wood, has continued to sell Tesla shares, with the latest sale amounting to $8.42 million. This is the second consecutive day of significant sales, following Tesla's recent rally and discussions about its potential in autonomous driving technology. Despite these sales, Ark remains optimistic about Tesla's future, projecting a stock price surge to $2,000 by 2027. Ark Invest also made key trades in Roblox Corp, Teladoc Inc, DraftKings Inc, and Ginkgo Bioworks Holdings Inc.

Portfolio Pulse from Benzinga Neuro

September 21, 2023 | 2:24 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.